Altimmune (NASDAQ:ALT) Coverage Initiated at Stifel Nicolaus

Stock analysts at Stifel Nicolaus began coverage on shares of Altimmune (NASDAQ:ALT) in a note issued to investors on Wednesday, MarketBeat.com reports. The firm set a “buy” rating and a $18.00 price target on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 141.61% from the stock’s previous close.

Several other equities analysts have also weighed in on ALT. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday, November 14th. UBS Group initiated coverage on Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $19.71.

Altimmune Stock Performance

Shares of ALT opened at $7.45 on Wednesday. The stock has a 50 day moving average price of $8.10 and a 200 day moving average price of $7.20. The stock has a market capitalization of $529.88 million, a price-to-earnings ratio of -4.81 and a beta of 0.22. Altimmune has a one year low of $5.28 and a one year high of $14.84.

Altimmune (NASDAQ:ALT) last issued its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03. The business had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter in the prior year, the firm earned ($0.39) earnings per share. On average, analysts predict that Altimmune will post -1.36 earnings per share for the current year.

Institutional Investors Weigh In On Altimmune

Institutional investors and hedge funds have recently modified their holdings of the company. Larson Financial Group LLC acquired a new position in Altimmune in the 3rd quarter valued at about $31,000. PFG Investments LLC acquired a new position in shares of Altimmune in the second quarter valued at approximately $67,000. Principal Financial Group Inc. purchased a new stake in Altimmune during the 2nd quarter worth approximately $70,000. XTX Topco Ltd acquired a new stake in Altimmune during the 2nd quarter worth approximately $96,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Altimmune by 190.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,688 shares of the company’s stock worth $98,000 after acquiring an additional 9,635 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.